thyroid cancer and glp-1 Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second “epidemic” of overdiagnosis? The Thyroid Twist: How GLP-1

Chin YH, Ng CH, Chew NW, et al

That is precisely why the documented starting dose is a conservative 2 mg once weekly and why the escalation is unhurried the ladder is calibrated to the combined receptor load, not to any one arm

In contrast, prolonged treatment with the GLP-1 receptor agonist semaglutide lowered perfusion compared with placebo (41)

This includes evaluations by a licensed medical provider, follow-up appointments, messaging access to clinicians, a 4-week supply of medication (if prescribed), and shipping

conducted a retrospective cohort study and found that there was a significantly lower risk of HHF in patients with T2DM, overweight/obesity, and HFpEF receiving GLP-1 RA plus SGLT2i therapy compared with the SGLT2i-only therapy, suggesting a potential incremental benefit of GLP-1 RA [81]

10.1007/s10555-024-10192-9 [DOI] [PMC free article] [PubMed] [Google Scholar] 9.Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares M, de Souza GA, Fidalgo TM, Araujo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Silva Ullmann O, Sloan T, Sloan KP LA (2022) GLP-1a: going beyond traditional use